Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

Cited In for PubMed (Select 17540852)

1.

Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes.

Merker JD, Roskin KM, Ng D, Pan C, Fisk DG, King JJ, Hoh R, Stadler M, Okumoto LM, Abidi P, Hewitt R, Jones CD, Gojenola L, Clark MJ, Zhang B, Cherry AM, George TI, Snyder M, Boyd SD, Zehnder JL, Fire AZ, Gotlib J.

Haematologica. 2013 Nov;98(11):1689-96. doi: 10.3324/haematol.2013.092379. Epub 2013 Jul 19.

2.

Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian JJ, Levine RL, Licht JD, Mullally A, Odenike O, Pardanani A, Silver RT, Solary E, Mughal T.

Blood Cancer J. 2011 Mar 4;1:e7. doi: 10.1038/bcj.2011.4.

3.

Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells.

Swierczek S, Nausova J, Jelinek J, Liu E, Roda P, Kucerova J, Jarosova M, Urbankova H, Indrak K, Prchal JT, Divoky V.

Am J Hematol. 2013 Feb;88(2):157-8. doi: 10.1002/ajh.23362. Epub 2012 Dec 24. No abstract available.

4.

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.

Godfrey AL, Chen E, Pagano F, Ortmann CA, Silber Y, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, McMullin MF, Boiron JM, Döhner K, Vannucchi AM, Besses C, Campbell PJ, Green AR.

Blood. 2012 Sep 27;120(13):2704-7. Epub 2012 Aug 16.

5.

Off-pump coronary artery surgery in a patient with essential thrombocythaemia: two life-threatening complications in the same patient.

Kaya K, Cavolli R, Telli A, Tasoz R.

BMJ Case Rep. 2009;2009. pii: bcr01.2009.1503. doi: 10.1136/bcr.01.2009.1503. Epub 2009 Aug 25.

6.

Thrombopoietin and hematopoietic stem cells.

de Graaf CA, Metcalf D.

Cell Cycle. 2011 May 15;10(10):1582-9. Epub 2011 May 15. Review.

7.
8.

Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Tefferi A.

J Cell Mol Med. 2009 Feb;13(2):215-37. doi: 10.1111/j.1582-4934.2008.00559.x. Epub 2008 Oct 23. Review.

9.

Pediatric essential thrombocythemia (ET) from the Czech Republic.

Samuelson SJ, Prchal JT.

Leuk Res. 2008 Mar;32(3):367-8. Epub 2007 Sep 7. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk